Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article from MarketBeat Media
These 3 Psychedelic Stocks Activated After Trump's Executive OrderAuthor: Nathan Reiff. Posted: 4/27/2026. 
Key Points
- The Trump administration's recent order in support of psychedelic drug treatments for various mental health conditions has prompted spikes of as much as nearly 80% for some of the companies in this space.
- Firms like Compass Pathways, AtaiBeckley, and Definium Therapeutics could see their drug candidates reach approval and commercialization much faster.
- PSIL is a broad exchange-traded fund offering access to the wider psychedelics industry for investors not keen to take on risk associated with a single speculative company.
- Special Report: The Biggest IPO Ever: Claim Your Stake Today
The Trump administration's April 2026 executive order in support of psychedelic drugs may have flown under the radar for many investors amid the Iran war and other high-profile domestic political stories, but the implications for this small — and growing — industry are substantial. Within days the FDA began to act, awarding priority review designations to selected companies developing drugs in this category, which can meaningfully shorten regulatory review times. Single-session wins were to be expected for some of the larger players in the psychedelics space, and several companies' shares did indeed jump. As time passes, however, it will be up to those developers to prove they have medicines to justify the newfound hype. These are some companies worth watching. A Promising Candidate Could Make It to Market Sooner, Preempting Financial Challenges
For a moment…
Forget about Trump’s ties to Israel.
Forget about reports of Iran’s nuclear program.
Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason. Click here to find out what it is.
One of the biggest beneficiaries of the executive order was biotech firm Compass Pathways (NASDAQ: CMPS), whose shares have surged by nearly 80% in the last month. The enthusiasm centers on COMP360, a drug candidate for treatment-resistant depression that received a priority review designation. For Compass, a key challenge has been maintaining operational viability while advancing a promising candidate. The company has recorded mounting net losses in recent years, and losses per share have widened even as the weighted average basic shares outstanding have more than doubled. A shorter runway to commercialization for COMP360 could materially help Compass address these hurdles. Although several analysts already rated the firm a Buy, it received a fresh wave of bullish ratings and higher price targets immediately after the executive order. It entered late April with eight of 10 analyst ratings at Buy and over 100% upside potential, even after the recent rally. Another Speculative Penny Stock With a Promising CandidateAnother clinical-stage biotech with a potential psychedelic-based treatment for certain types of depression, AtaiBeckley (NASDAQ: ATAI), also saw a stock surge in mid-April. Although Phase 3 trials of its BPL-003 don't begin until later in 2026, AtaiBeckley reported positive results from an earlier phase in April. With current sales of roughly $4 million annually, AtaiBeckley carries a sky-high price-to-sales (P/S) ratio in the 400s — a level that typically signals the shares are highly valued relative to revenue. As a pre-profit biotech, it also qualifies as a penny stock, with shares below $5 even after the boost. That makes ATAI a speculative investment likely to exhibit significant volatility. Still, momentum behind psychedelic treatments for mental health may help the company bring BPL-003 to market sooner than initially expected. Ten of 12 analysts track the stock positively, and the consensus price target of $14.63 implies more than 200% upside, substantially higher than CMPS. A Potential Generalized Anxiety Disorder Treatment and Strong Analyst SupportDefinium Therapeutics Inc. (NASDAQ: DFTX), formerly known as Mind Medicine, has also reported significant net losses in recent years. However, ending 2025 with $258 million in cash and equivalents gives it runway to advance MM120, a drug candidate for generalized anxiety disorder. Like the other candidates mentioned, MM120 targets a very large addressable market, and successful commercialization could transform Definium from a speculative play into an important biopharma player. DFTX shares have risen about 25% in the last month amid the executive order news, but analysts are relatively more optimistic about this stock than the others covered here. It has 14 Buy ratings and only one Sell, with forecasts implying roughly 70% upside potential. If the individual companies above feel too risky, investors looking for diversified exposure to the sector might consider a niche exchange-traded fund such as the AdvisorShares Psychedelics ETF (NYSEARCA: PSIL). This actively managed fund carries a relatively high expense ratio of about 1%, but it provides access to roughly two dozen companies in the space, allowing investors to benefit from breakthroughs while mitigating company-specific risk. PSIL also offers a dividend yield around 8.5%, which may further appeal to some investors. |
Post a Comment
Post a Comment